Related Experiment Video
Updated: May 20, 2026
Imaging Glioma Initiation In Vivo Through a Polished and Reinforced Thin-skull Cranial Window
Published on: November 20, 2012
The potential of RECK inducers as antitumor agents for glioma
1Department of Surgery, Far Eastern Memorial Hospital, Pan-Chiao, New Taipei, Taiwan, ROC.
Abstract:
Reversion-inducing cysteine-rich protein with Kazal motifs (RECK), a tumor and metastasis suppressor gene, is critical for the regulation of the invasive and metastatic activities of tumor cells. RECK is down-regulated in some malignancies and its expression is positively correlated with survival of patients with cancer. Patients with malignant glioma have poor prognosis. Since RECK expression decreases as the tumor stage progresses from less invasive grade II glioma to invasive glioblastoma multiforme, up-regulation of RECK by natural or synthetic agents might be a valuable therapeutic option for glioma. Histone deacetylase inhibitors and non-steroidal anti-inflammatory drugs have been widely used clinically and demonstrated to increase RECK expression in cancer cells, thus they might be used as RECK inducers. In this article, the functions of RECK and the role of RECK in glioma are reviewed, with emphasis on the potential application of RECK inducers in the treatment of glioma.
Insights
Reversion-inducing cysteine-rich protein with Kazal motifs (RECK) suppresses tumors. Increasing RECK expression may offer a new therapeutic strategy for treating malignant glioma, a type of brain cancer.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Reversion-inducing cysteine-rich protein with Kazal motifs (RECK) is a tumor and metastasis suppressor.
- RECK down-regulation correlates with malignancy and poorer patient survival.
- Malignant glioma patients have a poor prognosis, with decreasing RECK expression linked to tumor progression.
Purpose of the Study:
- To review the functions of RECK.
- To examine the role of RECK in glioma.
- To explore the potential of RECK inducers as a therapeutic strategy for glioma.
Main Methods:
- Literature review on RECK function and its role in glioma.
- Analysis of RECK expression patterns in different glioma grades.
- Evaluation of potential RECK-inducing agents, such as histone deacetylase inhibitors and non-steroidal anti-inflammatory drugs.
Main Results:
- RECK expression decreases with increasing glioma grade, from less invasive to glioblastoma multiforme.
- Certain clinical agents, including histone deacetylase inhibitors and NSAIDs, have been shown to increase RECK expression in cancer cells.
- Up-regulation of RECK presents a potential therapeutic avenue for glioma treatment.
Conclusions:
- RECK plays a critical role in regulating tumor invasion and metastasis.
- Targeting RECK expression, particularly through induction, holds promise for improving outcomes in malignant glioma patients.
- Further research into RECK inducers could lead to novel glioma therapies.
